Table 1.
Baseline characteristics of Canadian Multicentre Osteoporosis Study population
| Characteristic | All participants
|
Those who completed 10-year interview
|
||
|---|---|---|---|---|
| SSRI/SNRI non-users (N = 6,453) | SSRI/SNRI users (N = 192) | SSRI/SNRI non-users (N = 3678) | SSRI/SNRI users (N = 333) | |
| Sex | ||||
| Female (%) | 4,580 (71) | 160 (83.3)** | 2,677 (72.8) | 285 (85.6)** |
| Age at enrollment (years ± SD) | 65.71 (8.9) | 65.25 (8.7) | 63.43 (7.9) | 63.65 (8.0) |
| Education level at enrollment | ||||
| High school or higher (%) | 3,896 (60.4) | 125 (65.1) | 2,408 (65.5) | 198 (59.5)** |
| Employment status | ||||
| Full employed (%) | 1,082 (16.8) | 24 (12.5) | 251 (6.8) | 10 (3.0)** |
| Regular activity or program | ||||
| Yes (%) | 3,699 (57.3) | 106 (55.2) | 2,225 (60.5) | 182 (54.7) |
| Number of sedentary hours/day (mean ± SD) | 13.85 (2.9) | 14.11 (3.1) | 13.84 (2.9) | 13.89 (3.2) |
| Current smoker | ||||
| Yes (%) | 930 (14.4) | 39 (20.3) | 458 (12.5) | 53 (15.9) |
| Alcohol intakea—median (IQb) | 0.46 (3) | 0.23 (2)** | 0.46 (4) | 0 (2)** |
| Number of comorbiditiesc | ||||
| 1 or more | 1,583 (24.5) | 70 (36.5)** | 639 (17.4) | 72 (21.6) |
| Depressive symptomsd | ||||
| Yes (%) | 885 (13.8) | 75 (39.7)** | 380 (10.4) | 85 (25.7)** |
| Vertebral deformities (Genant grade 1) | ||||
| Yes (%) | 1,395 (21.6) | 29 (15.1)* | 701 (19.1) | 72 (21.6) |
| Vertebral deformities (Genant grade 2) | ||||
| Yes (%) | 538 (8.3) | 16 (8.3) | 287 (7.8) | 35 (10.1) |
| BMD at enrollment (mean ± SD) | ||||
| Total hip (g/cm2) | 0.88±0.16 | 0.86±0.14* | 0.90±0.15 | 0.86±0.14** |
| Lumbar spine (g/cm2) | 0.95±0.18 | 0.95±0.18 | 0.96±0.18 | 0.94±0.17 |
| Femoral neck (g/cm2) | 0.72±0.13 | 0.70±0.11 | 0.73±0.12 | 0.71±0.12 |
| Falls in previous month before baseline | 398 (6.2) | 31 (16.1) | 220 (6) | 24 (7.2) |
| Drug use | ||||
| Other antidepressants | 251 (3.9) | 19 (9.9)** | 182 (4.9) | 43 (12.9)** |
| Anxiolytics | 294 (4.6) | 28 (14.6)** | 221 (6.0) | 57 (17.1)** |
| Antihypertensives | 1,276 (19.8) | 34 (17.7) | 776 (21.1) | 69 (20.7) |
| Antipsychotics | 28 (0.4) | 0 (0) | 10 (0.3) | 7 (2.1)** |
| Biphosphonates | 112 (1.7) | 4 (2.1) | 853 (23.2) | 94 (28.2)* |
| Corticosteroids (oral + IV) | 89 (1.4) | 2 (1) | 69 (1.9) | 5 (1.5) |
| Intake in previous 12 months median (IQ) | ||||
| Calcium (mg/day) | 902.9 (754.0) | 969.4 (810.9) | 1,234 (959.4) | 1,272 (805.5) |
| Vitamin D (mcg/day) | 6.6 (8.9) | 8.7 (9.4) | 10.2 (17.3) | 10.4 (17.0) |
Variables for which a statistically significant difference exists, based on the chi-square test for categorical and independent groups t test or Wilcoxon test for continuous variables, between SSRI/SNRI users and non-users are indicated
BMD bone mineral density
*
p<0.05;
**
p<0.001
a
Number of alcoholic beverages per week in previous 12 months
b
IQR (interquartile range): Q3–Q1
c
Based on modified Charlson index
d
Depressive symptoms based on score <52 on the MHI-5 scale or <42 on the MCS scale